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Abstract The first known function of Ku70 is as a DNA
repair factor in the nucleus. Using neuronal neuroblastoma
cells as a model, we have established that cytosolic Ku70
binds to the pro-apoptotic protein Bax in the cytosol and
blocks Bax’s cell death activity. Ku70-Bax binding is regulat-
ed by Ku70 acetylation in that when Ku70 is acetylated Bax
dissociates from Ku70, triggering cell death. We propose that
Ku70may act as a survival factor in these cells such that Ku70
depletion triggers Bax-dependent cell death. Here, we ad-
dressed two fundamental questions about this model: (1)
Does all Bax, which is a cytosolic protein, bind to all cytosolic
Ku70? and (2) Is Ku70 a survival factor in cells types other
than neuronal neuroblastoma cells? We show here that, in
neuronal neuroblastoma cells, only a small fraction of Ku70
binds to a small fraction of Bax; most Bax is monomeric.
Interestingly, there is no free or monomeric Ku70 in the cyto-
sol; most cytosolic Ku70 is in complex with other factors
forming several high molecular weight complexes. A fraction
of cytosolic Ku70 also binds to cytosolic Ku80, Ku70’s bind-
ing partner in the nucleus. Ku70 may not be a survival factor
in some cell types (Ku70-depletion less sensitive) because
Ku70 depletion does not affect survival of these cells. These
results indicate that, in addition to Ku70 acetylation, other
factors may be involved in regulating Ku70-Bax binding in
the Ku70-depletion less sensitive cells because Ku70 acetyla-
tion in these cells is not sufficient to dissociate Bax fromKu70
or to activate Bax.
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Introduction
Bax, a pro-apoptotic protein, belongs to the Bcl-2 family of
proteins [1]. Activation of Bax plays an important role in both
intrinsic and extrinsic apoptotic pathways. Activation of Bax
can be achieved by binding to other Bcl-2 proteins, such as
Bcl-2 or Bcl-Xl. Other Bcl-2 family proteins, such as that
those contain only one Bcl-2 homology domain 3 (BH-3),
can also activate Bax by directly binding to Bax [2].
However, Bax activity is also regulated by binding to other
non-Bcl-2 proteins, such as humanin, 14-3-3, and Ku70 [3–5].
Using a neuroblastic type (N-type) of neuroblastoma (NB)
cells, SH-SY5Y, we have established a model in which Bax
activation is regulated by binding to the cytosolic Ku70 [6].
Ku70 was originally described as an auto-antigen [7].
However, subsequently, it was found that when dimerized
with Ku80, Ku70 binds to the double strand break DNA to
initiate non-homologous end-joining (NHEJ) repair [8] pro-
cess. But, in a yeast two hybrid study, Ku70 was also found to
be one of the factors that bind Bax [5]. The same study
showed that cytosolic Ku70 binds to Bax and inhibits Bax’s
pro-apoptotic activity. We and others have demonstrated that
Ku70-Bax binding is regulated by acetylation of Ku70 such
that when Ku70 is acetylated by the CREB-binding protein
(CBP), Bax dissociates from Ku70 [9, 10]. The dissociated
Bax enters mitochondria resulted in release of cytochrome C
that triggers cell death. Ku70 acetylation is regulated by a
class II histone deacetylase (HDAC), HDAC6. HDAC6 binds
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and deacetylates cytosolic Ku70 such that inhibition of
HDAC6, either by using class I and II HDAC inhibitors
(HDACI), such as suberoylanilide hydroxamic acid (SAHA)
and trichostatin A (TSA), HDAC6-specific inhibitors,
tubacin, or by depleting HDAC6 using small interfering
RNA (siRNA), increases cytoplasmic Ku70 acetylation that
resulted in Bax dissociation [11]. This model suggests that all
cytosolic Bax binds to and is regulated by Ku70, which is
inconsistent with studies demonstrating that Bax is monomer-
ic and inactive in the cytosol [12]. This model is based on
previous studies showing that in unstimulated cells, when
anti-Bax antibodies (6A7) that recognizes activated Bax are
used to pull down endogenous Bax, only a small amount of
Bax was immunoprecipitated. Following treatment with Bax-
activating compounds, like staurosporine, 6A7 was able to
pull down more Bax [13], presumably activated Bax.
Furthermore, gel filtration chromatography studies revealed
that endogenous Bax is found in fractions at molecular weight
corresponding to 29 kD proteins [14]. Thus, if Bax exists as
monomers in the cytosol, how does binding of Ku70 regulate
Bax’s activity? What is the stoichiometry of the binding be-
tween Ku70 and Bax? Does cytosolic Ku70 bind to all Bax in
the cytosol? In this study, we have addressed two questions:
first, does all Bax bind to all cytosolic Ku70?Our results show
that there is only a small fraction of total cytosolic Ku70 bind-
ing to a small fraction of total Bax. The majority of Bax is
monomeric. However, most cytosolic Ku70 bind to other fac-
tors forming several high molecular weight complexes. There
is no free or monomeric Ku70 found in the cytosol. These
results suggest that other factors may also regulate Ku70-
Bax binding by restricting the availability of Ku70 that can
bind to Bax.
The second question is that is Ku70 a survival factor
in all cells types other than the N-type NB cells?
Previously, we have shown that Ku70 plays a survival
role in regulating Bax pro-apoptotic activity because de-
pletion of Ku70 in SH-SY5Y cells results in Bax-
dependent cell death [9]. However, studies have shown
that, in cells, such as HeLa and HEK-293, depleting
Ku70 using Ku70-specific siRNA did not induce cell
death [5, 10]. These results suggest that there may be
at least two cell types in terms of Ku70 regulating Bax
function: one is Ku70-depletion sensitive cells, in which
Ku70 acts as a survival factor (like that in SH-SY5Y
cells). These cells are sensitive to Ku70 depletion,
knocking down Ku70 in these cells induces cell death.
The second cell type is less sensitive to Ku70 depletion
(like that in HeLa cells and HEK-293 cells), in which
Ku70 is not required for survival because knocking
down Ku70 in these cells does not induce cell death.
Here, we provided evidence that in multiple cell types
(SHEP-1, ES2, A2780, and HEK-293T cells), depletion
of Ku70 does not affect cell survival. Interestingly, these
cells are also less sensitive to HDACI killing compared
to that of N-type NB cells. Moreover, in these cells,
while HDACI treatment increases cytosolic Ku70 acety-
lation, Bax is neither activated nor does it dissociate
from Ku70. These results suggest that there may be an-
other mechanism that regulates Ku70-Bax formation and
Bax activation in Ku70-depletion less sensitive cells.
Materials and methods
Cell culture
HEK-293T, two ovarian cancer cell lines (ES2 and A2780)
and human NB cell lines SH-SY5Y, SH-EP1, GOTO, KCN-
69n, and LA1-5s were cultured in modified Eagle’s minimum
essential medium (MEM) supplemented with sodium pyru-
vate and 10 % fetal bovine serum, and maintained at 37 °C
in a humidified 5 % CO2 incubator.
Cell viability assays
Cell viability was determined by either (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tetrazo-
lium reduction assay or trypan blue exclusion assay. For the
MTT assay, 96-well plates were used. N-type SH-SY5Y, S-
type SHEP1 human NB cell lines treated with various concen-
trations of SAHA, and the human ovarian cancer cell lines
A2780 and ES2 were treated with varying concentrations of
TSA. The viability of the cell lines was determined 24 and
48 h post-treatment by MTT assay as previously described
[15]. All experiments were carried out three times with tripli-
cates in each experiment, and the average values and standard
deviations were calculated.
Analysis of apoptosis
SH-SY5Y and HEK-293T cells grown in 60-cm plates were
treated either with the solvent DMSO or with the SAHA
(4 μM). Twenty-four hours after treatment, the cells were
washed and suspended in annexin-binding buffer and stained
with annexin V-APC and propidium iodide (PI). Induction of
apoptosis was measured using a CyAn ADP Analyzer
(Beckman Coulter, Inc., Indianapolis, IN) at the University
of Michigan Flow Cytometry Core. The apoptotic and necrot-
ic cells were identified based on phosphatidylserine staining
with annexin on the outer leaflet of the cell membranes
(apoptosis) and DNA staining by PI (necrosis and late apopto-
sis). Results from three independent experiments were
analyzed.
13904 Tumor Biol. (2016) 37:13903–13914
siRNA-mediated silencing and over expression
of Flag-Ku70 and Flag-Ku80
For Ku70 knockdown experiments using siRNA, human NB
cell lines SH-SY5Y, SH-EP1, GOTO, KCN-69n, and LA1-5s,
and human ovarian cancer cell lines A2780 or ES2 cells were
plated at a density of ∼2 × 106 cells per 10-cm plate 24 h
before transfection. The following day, the cells were
transfected either with smart pool Ku70 siRNA (silencing
RNA) or with the scrambled non-targeting siRNA
(Dharmacon Inc.), using nucleofector kit V (Amaxa) as per
the manufacturer’s instruction. Mock transfection as well as
the non-targeting siRNA transfection served as controls. The
level of Ku70 was determined 72 h after transfection by sodi-
um dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) using Ku70 antibodies. Either glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) or β-tubulin was used
as a loading control. The viability of cells after knockdown
was measured by counting cells using trypan blue exclusion
analysis.
Western blot analysis
The proteins were separated by SDS-PAGE, transferred to
polyvinylidene difluoride (PVDF) membrane and then the
blot was probed for different antibodies specific for different
proteins. The following antibodies were used for western blot
analyses: Ku70 (N3H10) from Santa Cruz; Ku80 (no. 2753),
Bax (no. 2772S), anti-Bax antibody (6A7) (ab5714), cyto-
chrome c oxidase subunit IV (COX IV) (no. 4844), and acet-
ylated lysine (Ac-K-103) from Cell Signaling; and GAPDH
(6C5) from Millipore and β-tubulin from Upstate. The pres-
ence of protein was visualized by using Lumigen enhanced
chemiluminescence (ECL) plus PS-3.
Immunoprecipitation
Co-immunoprecipitation of Ku70, Ku80, and Bax were per-
formed in CHAPS buffer according to the protocol described
by Sawada et al. [5] with some modifications. Cells were
lysed on ice for 30 min using lysis buffer (20 mM HEPES,
pH 7.5, 120 mM NaCl, and 1 % CHAPS). The extraction
solution was spun twice at 3000 rpm for 10 min. The protein
concentration was determined by Bio-Rad protein assay. One
milligram of protein in 500 μl of lysis buffer was used for
immunoprecipitation.
Subcellular fractionation: cytosolic and mitochondrial
fraction
Cells were grown in 10-cm plates to 80 % confluency. The
cells were washed twice with PBS, and the cells were
suspended in the mitochondrial isolation buffer (5 mM
HEPES pH 7.5, 210 mM Mannitol, 70 mM Sucrose, 1 mM
EDTA) in 1 million cells/100 μl of buffer. The cells were
swollen on ice for 30 min and were dounced in a dounce
homogenizer 50 times. The lysed cells were spun at
1500 rpm for 5 min at 4 °C. The supernatant was re-spun at
3000 rpm for 10 min. The remaining supernatant, which
contained cytosolic and mitochondrial fractions, was re-spun
at 10,000 g for 20 min at 4 °C. The supernatant was collected
as the cytosolic fraction and the pellet was collected as mito-
chondrial fraction. The mitochondrial pellet was washed once
with the mitochondrial isolation buffer. Equal amounts of cy-
tosolic and mitochondrial protein were separated by SDS-
PAGE. The purity of the mitochondrial and cytosolic fractions
was determined by immunoblotting with COX IV and β-tu-
bulin, respectively.
DC4 cross-linking
DC4 cross-linker was used in our cross-linking analyses [16].
Cross-linking was carried out in a buffer containing 100 mM
HEPES (pH 7.5) and 150 mMNaCl. Each cross-linking reac-
tion contained 10–15 μg of cytosolic or nuclear proteins with
0, 0.1, 0.2, 0.4, 0.8, or 1.6 mM of DC4 per sample. The cross-
linking reaction was carried out on ice for 30 min. The reac-
tion was stopped by SDS-loading buffer. Cross-linked sam-
ples were separated by 10 % SDS-PAGE, and the blot was
probed with Ku70, Ku80, or Bax antibodies.
Gel filtration
Gel filtration chromatography was carried out using a Bio-
Rad Biologic DueFlow system with a Superdex 200 HR 10/
30 column at a flow rate of 0.5 ml per min. One milligram of
cytosolic extracts was injected into the column. The running
buffer was the same as the extraction buffer containing 20mM
HEPES (pH 7.5), 120 mM NaCl, and 1 % CHAPS. Half a
milliliter fraction was collected. Twenty microliters of each
fraction was separated by SDS-PAGE, and the blot was
probed with Ku70, Ku80, or Bax antibodies.
Results
Cytosolic Ku70 forms high molecular weight complexes,
while Bax is found to be mainly monomeric
Gel filtration chromatograph results show that the majority of
cytosolic Ku70 in SH-SY5Y cells was found in fractions cor-
responding to high molecular weight complexes. In contrast,
Bax was found in fractions at around 29kD (Fig. 1a), as pre-
viously described [14]. There was little overlap between Ku70
and Bax. These results indicate that not all cytosolic Ku70
interacts with all Bax in the cytosol; there is only a small
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number of fractions found to contain both Ku70 and Bax.
Furthermore, the results indicate that the majority of Ku70
was found in fractions corresponding to large molecular com-
plexes. Interestingly, the pattern of Ku80 in the gel filtration
chromatography was different from that of Ku70. The major-
ity of Ku80 was found in fractions corresponding to 200 kD.
To investigate whether Ku70 is found in one high molecu-
lar weight complex, as shown Fig. 1a, or in multiple com-
plexes, we have conducted a cross-linking experiment using
a cross-linker, DC4 [16]. We cross-linked cytosolic extracts
and nuclear extracts of SH-SY5Y cells with various concen-
trations of DC4 as shown in Fig. 1b. The cross-linked com-
plexes were separated by SDS-PAGE, and the blot was probed
with Ku70, Ku80, or Bax antibodies. Cytosolic Ku70 was
found in at least three high molecular weight complexes,
while nuclear Ku70 was found in only two high molecular
weight complexes (Fig. 1b). One of the Ku70 containing com-
plexes (in the cytosol and in the nucleus) also contained Ku80.
Most importantly, however, there was no monomeric Ku70 or
Ku80 in the cytosol and in the nucleus because monomeric
Ku70 and Ku80 disappeared in the SDS-PAGE immunoblots
when increasing amounts of DC4 were used. The Bax cross-
linking result was also consistent with the model in that only a
very small fraction of Bax was complexed with Ku70; increas-
ing cross-linker concentration did not seem to reveal a Bax-
Ku70 complex due to low level of this complex.
Ku80 mainly forms a complex with Ku70 in cells
Ku80 when analyzed by gel filtration chromatography was
found in fractions close to the fractions containing Bax
(Fig. 1a). Ku80 only overlapped with Ku70 in a few fractions.
These results suggest that Baxmay interact with Ku80 in cells.
However, our immunoprecipitation results shown in Fig. 2a
did not support this hypothesis, at least in SH-SY5Y cells. Our
results show that Ku70 was precipitated by anti-Bax antibody
in cytosolic extracts of control SH-SY5Y cells but not in cy-
tosolic extracts treated with SAHA (4 μM) for 48 h. In con-
trast, Ku80 was not precipitated by the anti-Bax antibody in
SAHA-treated or non-treated cytosolic extracts. These results
suggest that despite the gel filtration chromatography results
















Fig. 1 The majority of cytosolic
Ku70 is found in high molecule
weight complexes. a Cytosolic
SH-SY5Y cell extracts were
analyzed by Superdex 600 HR
10/30 gel filtration
chromatography. Twenty
microliter of each fraction
(0.5 ml) was separated by sodium
dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE),
and the blot was probed with
Ku70, Bax, or Ku80 antibodies. b
Cytosolic extracts were cross-
linked using DC4 (0, 0.1, 0.2, 0.4,
0.8, 1.6 mM) as shown. Cross-
linked proteins were separated by
10 % SDS-PAGE, and the blot
was probed with Ku70, Ku80, or
Bax antibodies
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fractions containing Bax, these two proteins might not interact
with each other in these cells.
Gel filtration chromatography showed that the elution
patterns of Ku70 and Ku80 were very different. There
was no significant overlap between Ku70 and Ku80
(Fig. 1a). However, in the cross-linking study, one of
the Ku70-containing complexes was Ku80 positive when
probed with a Ku80 antibody. We then asked whether
Ku70 and Ku80 interact with each other in the cytosol
of SH-SY5Y cells. We immunoprecipitated Ku70 or
Ku80 using Ku70 or Ku80 antibodies in the cytosolic
extracts of SH-SY5Y cells with or without 48 h SAHA
(4 μM) treatment. Normal mouse serum (NMS) or nor-
mal rabbit serum (NRS) was used as a negative control
for Ku70 antibody or Ku80 antibody, respectively.
Immunoprecipitates were separated by SDS-PAGE, and
the blot was probed with Ku70 or Ku80 antibodies.
Figure 2b shows that Ku70 or Ku80 immunoprecipitation
pulled down Ku80 or Ku70, respectively, in cytosolic
extracts that were either treated or untreated with
SAHA. These results indicate that Ku70 interacted with
Ku80 in the cytosol of SH-SY5Y cells, and this interac-
tion was not affected by SAHA treatment.
Ku70 depletion induces apoptosis specifically in SH-SY5Y
cells but not in other cancer cell types
To address whether Ku70 depletion induces cell death in cell
types other than SH-SY5Y cells, we knocked down Ku70
using Ku70 siRNA in several cancer cell lines: N-type NB
cells (SH-SY5Y), stromal-type (S-type) NB cells (SHEP-1),
ovarian cancer cells (A2780 and ES2), and HEK-293T. Ku70
siRNA or scrambled siRNA was transfected in various cell
lines. Forty-eight hours after transfection, the cell viability
was determined by trypan blue exclusion assay. The results
shown in Fig. 3a indicate that, except the NB N-type SH-












































Fig. 2 No interaction between
Bax and Ku80. a SH-SY5Y cells
were treated with suberoylanilide
hydroxamic acid (SAHA) (4 μM)
for 48 h. Control cells received
the same volume of DMSO.
Cytosolic extracts were
immunoprecipitated using an
anti-Bax antibody. Normal rabbit
serum (NRS) was used as a
negative control. The
immunoprecipitated complex was
separated by sodium dodecyl
sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), and
the blot was probed with Ku70,
Ku80, or Bax antibodies. b SH-
SY5Y cells were treated with
SAHA (4 μM) for 48 h. Control
cells received the same volume of
DMSO. Cytosolic extracts were
immunoprecipitated using Ku70
or Ku80 antibodies. Normal
mouse serum for Ku70
immunoprecipitation or normal
rabbit serum for Ku80




separated by SDS-PAGE, and the
blot was probed with Ku70 or
Ku80 antibodies
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depletion of Ku70 in other cell types, such as in SHEP1, ES2,
A2780, and HEK-293T cells, did not affect cell viability.
Ku70 depletion reduces cell viability in N-type NB cells
To determine whether Ku70 depletion-induced reduction of
cell viability is specific to only one type of N-type NB cells,
SH-SY5Y cells, we determined cell viability in three other N-
type NB cells (IMR32, KCN-69n, and GOTO) after Ku70
depletion using siRNA. We used SH-SY5Yas a positive con-
trol and SHEP-1 and LA1-5s, two S-type NB cells as negative
controls. Forty-eight hours after siRNA transfection, cell via-
bility was determined by trypan blue exclusion assay. The
results shown in Fig. 3b indicate that like SH-SY5Y cells, cell
viability of three other N-type NB cells was reduced by Ku70
siRNA transfection while the cell viability of the two S-type
NB cells was not affected. These results suggest that not only
SH-SY5Y cells but also N-type NB cells require Ku70 for
survival as depletion of Ku70-induced cell death.
Ku70, Ku80, and Bax levels are similar in all cell types
Next, we explored the differences between the Ku70-
depletion sensitive cells and the Ku70-depletion insensitive
cells. Here, we tested a hypothesis in which Bax requirement
for cell death may be different in these Ku70-depletion insen-
sitive cells. One possibility is that Bax may be absent in these
cells so that Bax is no longer a cell death factor. Thus, deple-
tion of Ku70 will not have any effect on cell survival. We
determined the protein expression of Ku70, Ku80, and Bax
in the cytosolic extracts and in the whole cell extracts in SY-
SH5Y, SHEP-1, ES2, A2780, and HEK-293T cells. We
a
b











































Fig. 3 Ku70 depletion reduces cell viability in SH-SY5Y cells but not in
SHEP-1, ES2, A2780, or HEK-293T cells. a Cells received two
sequential transfections of Ku70-specific small interfering RNA
(siRNA). Scrambled siRNA was used a negative control. Two days
after the last transfection, cell viability was determined by trypan blue
exclusion assay. The degree of Ku70 depletion was determined by SDS-
PAGE using the anti-Ku70 antibody. β-Tubulin was used as a loading
control. b Cells received two sequential transfections of Ku70-specific
siRNA. Scrambled siRNAwas used as a negative control. Two days after
the last transfection, cell viability was determined by trypan blue
exclusion assay
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separated these factors by SDS-PAGE and probed the blot
with Ku70, Ku80, or Bax antibodies. β-Tubulin was used as
a loading control. Figure 4a shows that, in whole cell extracts,
the level of Ku70, Ku80, or Bax in all cell lines was similar,
except in ES2 that had low levels of Bax. In the cytosolic
extracts, the β-tubulin loading control was uneven; it was
higher in SH-SY5Yand SHEP-1 cells, and to some extent also
in HEK-293Tcells, compared to that of ES2 and A2780 cells.
However, the Bax level followed the same pattern as that of
the β-tubulin loading control, being higher in SH-SY5Y,
SHEP-1, and HEK-293T cells but low in other cell types.
The level of cytosolic Ku70 and Ku80 was similar despite
the variations in β-tubulin loading control. While we did not
conduct a densitometry analysis of these bands, we felt that we
can conclude from these results that there were no big varia-
tions in the level of Bax and Ku70 in the cytosolic extracts of
SH-SY5Y, SHEP-1, and HEK-293T cells. These results
suggest that differences in the sensitivity to Ku70 depletion
were not due to the differences in the Bax or Ku70 levels.
Ku70-depletion sensitive and insensitive cells have similar
cytosolic Ku70 complex pattern
Using gel filtration chromatography and cross-linking studies,
we have shown that in Ku70-depletion sensitive SH-SY5Y
cells, Ku70 forms several high molecular weight complexes
and that only a small fraction of Ku70 and Bax binds to each
other (Fig. 1a). Here, we show that, like that of SH-SY5Y
cells, Ku70-depletion insensitive cells (HEK-293T and
A2780 cells) had similar patterns in gel filtration chromatog-
raphy (Fig. 4b). These results suggest that there were no gross
differences in terms of Ku70 or Bax distribution in the Ku70-



































































































Fig. 4 Ku70-depletion sensitive or insensitive cells have similar levels of
Ku70, Ku80, or Bax, but they differ in their response to HDACI-induced
cell death. aCytosolic extracts or whole cell extracts of SH-SY5Y, SHEP-
1, ES2, A2780, and HEK-293T cells were separated by SDA-PAGE and
blotted with Ku70, Ku80, or Bax antibodies. β-Tubulin was used as a
loading control. b Cytosolic HEK-293T or A2780 cell extracts were
analyzed by Superdex 600 HR 10/30 gel filtration chromatography.
Twenty microliters of each fraction (0.5 ml) were separated by SDA-
PAGE, and the blot was probed with Ku70 or Bax antibodies. c Cells
were plated into 96-well plates. One day later, they were treated with
various concentrations of suberoylanilide hydroxamic acid (SAHA) as
shown. There were at least three wells per concentration. Forty-eight
hours following SAHA treatment, cell viability was determined by
MTT assay. The results of the MTT assay were expressed as percent of
DMSO-treated control (mean ± SD)
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Different responses to SAHA treatment in different cell
types
We have shown previously that SH-SY5Y cells are sensitive
to HDACI treatments. Using SAHA, TSA (both class I and II
HDAC inhibitors), or tubacin (an HDAC6-specific inhibitor),
we have shown that HDACIs induce Ku70 acetylation, which
resulted in Bax dissociation and apoptotic cell death [11, 17,
18]. Here, we explored the differences between Ku70-
depletion sensitive and Ku70-depletion insensitive cells in
terms of their response to HDAC inhibitor treatment. Cells
were treated by 48 h with SAHA (0, 0.5, 1, 2, and 4 μM).
Cell viability was determined by MTT assay. The results in
Fig. 4c show that SH-SY5Y cell viability was reduced to
20 %, while the cell viability of other Ku70-depletion less
sensitive cells were only reduced to 50 % (HEK-293T and
A278) and to 80 % (20 % reduction for SHEP-1 cells).
There were clear differences in terms of the cell viability re-
sponse to HDACI treatment between Ku70-depletion sensi-
tive and Ku70-depletion less sensitive cell types.
HDACI induces cytosolic Ku70 acetylation but not
Ku70-Bax dissociation in Ku70-depletion insensitive cell
lines
We have previously shown that in Ku70-depletion sensi-
tive cells (such as SH-SY5Y cells), HDACI treatment
induces Ku70 acetylation, Bax dissociation from Ku70,
and apoptotic cell death. In Fig. 4c, we show that the
Ku70-depletion insensitive cells only had a partial re-
sponse to HDACI treatment. Thus, we next explored
whether the Ku70-Bax complex in the Ku70-depletion
insensitive cells have similar response to HDACI. We
first tested whether Ku70 is acetylated in Ku70-
depletion less sensitive cells in response to HDACI. We
treated the cells with SAHA (4 μM) for 48 h. Cytosolic
extracts were immunoprecipitated using an anti-acetyl-
lysine antibody (Ac-K-103). The immunoprecipitates
were separated by SDS-PAGE and probed with an anti-
Ku70 antibody. The results shown in Fig. 5a indicate that
in both cell types, Ku70-depletion sensitive (SH-SY5Y)
and Ku70-depletion less sensitive cells (SHEP-1, ES2,
A2780, and HEK-293T), cytosolic Ku70 was acetylated
following HDACI treatment.
We have shown previously that in SH-SY5Y cells, Ku70
acetylation, either by inhibiting HDAC6 or by depleting
HDAC6, results in Bax dissociation causing apoptotic cell
death [11]. Here, we asked whether Bax dissociates from
Ku70 following HDACI treatment in Ku70-depletion less
sensitive cells. In ES2 and HEK-293T cells, 48 h following
TSA (10 μM) or SAHA (4 μM) treatment, respectively, we
immunoprecipitated Bax using a Bax-specific antibody.
Normal rabbit serum (NRS) was used as a negative control.
The immunoprecipitates were separated by SDS-PAGE, and
the blot was probed with anti-Bax antibodies or anti-Ku70
antibodies. The results in Fig. 5b, c show that the Bax anti-
body immunoprecipitated Ku70 in the cytosolic extracts of
both cell types that were treated with or without HDACI.
These results suggest that, unlike those in SH-SY5Y cells,
Bax did not dissociate from Ku70 even though Ku70 was
acetylated following HDACI treatment.
Bax is not activated following HDACI treatment
in Ku70-depletion insensitive cell
While the results shown in Fig. 5a demonstrate that Ku70 was
acetylated following HDACI treatment, and the results in
Fig. 5b, c show that Bax did not dissociate from Ku70 in the
Ku70-depletion less sensitive cells, it is not clear whether Bax
was activated and induced apoptosis even it still bounds to
Ku70. To address these questions, we have examined several
key features of cells undergoing apoptosis.
We first treated HEK-293T and SH-SY5Y cells with
SAHA (4 μM). Twenty-four hours later, we determined the
viability and apoptosis of treated cells using annexin V-APC/
PI dual staining by flow cytometry. The results shown in the
left panel of Fig. 6a indicate that treatment of HEK-293T cells
with SAHA did not change viability, as greater than 99 % of
cells were not stained by either PI or annexin V. But in SH-
SY5Y cells, SAHA treatment decreased the viability of cells
from 94.7 to 77.1 % (top and bottom right panels of Fig. 6a).
Similarly, in HEK-293Tcells, SAHA treatment did not induce
any increase in annexin V positive cells. But in SH-SY5Y
cells, SAHA treatment increased annexin V positive cells
from 5.1 % (control) to 22.8 % (SAHA treated) with a P value
equal to 0.014 (two-tailed t test, N = 3).
Next, we directly asked whether Bax was activated follow-
ing HDACI treatment in Ku70-depletion sensitive cells (SH-
SY5Y) and Ku70-depletion less sensitive cells (HEK-293T).
We used an anti-Bax antibody (6A7) in an immunoprecipita-
tion experiment. This antibody binds to the N-terminal of Bax
when Bax is activated [19]. Using this method, we demon-
strated that in control cells, Bax activation was very low in
both SH-SY5Y cells and in HEK-293T cells (Fig. 6b).
However, 24 h following SAHA (4 μM) treatment, there
was a significant increase in Bax activation in SH-SY5Y cells
(increase in 6A7 antibody pull down). In contrast, there was
no increase in 6A7 antibody pull down in HEK-293T cells.
These results suggest that, in Ku70-depletion insensitive cells,
HDACI treatment did not induce Bax activation.
Anothe r approach was to tes t whe the r Bax
translocated to the mitochondria following HDACI treat-
ment. The results in Fig. 6c show that the level of Bax in
the mitochondria in SH-SY5Y cells was increased 8 h
following SAHA (4 μM) treatment. In contrast, in the
HEK-293T cells, SAHA treatment did not alter the level
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of Bax in the mitochondria. These results are consistent
with the results shown in Fig. 6a, b following HDACI
treatment in Ku70-depletion sensitive cells (SH-SY5Y);
Bax was activated and translocated into the mitochon-
dria. But in Ku70-depletion less sensitive cells (HEK-
293T), Bax was not activated and, therefore, there was
no change in Bax level.
In the last test, we studied the cleavage of pro-caspase
3, a downstream target of Bax activation, following
HDACI treatment. We used an anti-caspase 3 antibody
that recognizes both pro-caspase 3 and cleaved caspase
3. Both SH-SY5Y cells and HEK-293T were treated with
SAHA (4 μM) for 24 h, equal amounts of cytosolic ex-
tracts from treated and untreated cells were separated by
SDS-PAGE, and the blot was probed with the anti-caspase
3 antibody. β-Tubulin was used as a loading control. The
results in Fig. 6d demonstrated that there was a basal
cleavage of pro-caspase 3 in both cell types. However,
in SAHA-treated HEK-293T cells, there was no difference
in caspase 3 cleavage compared to the untreated cells. In
contrast, SAHA-treated SH-SY5Y cells had markedly re-
duced pro-caspase 3 level and increased cleaved caspase
3. These results suggest that, as predicted, HDACI treat-
ment of SH-SY5Y cells activated Bax, resulting in Bax
translocation to the mitochondria, leading to activation of
caspase 3 (cleavage of pro-caspase 3). In HEK-293T cells,
HDACI treatment did not activate Bax; Bax did not trans-
locate into mitochondria and did not cleave pro-caspase 3.
Discussion
One of the focuses of this study was to answer a fundamental
question: how much cytosolic Ku70 and Bax bind to each
other in cells. A study by Sawada et al. stated that “a large
proportion of the Bax population is associated with Ku70 in
normal cells” [5]. However, this statement is not consistent
with the published results showing that Bax is found to be
inactive and monomeric in the cytosol [14]. In contrast, our
results are consistent with this monomeric Bax model. We
have shown that, in SH-SY5Y cells, which are Ku70-
depletion sensitive, only a small fraction of cytosolic Ku70
binds to a small fraction of Bax. The majority of Bax is mo-
nomeric, and the majority of Ku70 is in complex with other
factors, including Ku80, forming several high molecular
weight complexes. Interestingly, there is no free Ku70 or mo-
nomeric Ku70 found in the cytosol.
We have proposed that Ku70 acts as a survival factor
to protect the cells from dying of Bax-dependent apopto-
sis. How can a small amount of cytosolic Ku70 that
binds to only a small amount of Bax protect the cell
from dying? We believe that cells throughout life
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Fig. 5 Cytosolic Ku70 is acetylated by histone deacetylase inhibitors
(HDACI) in cells, and Bax did not dissociate from Ku70 in ES2 and in
HEK-293T cells following HDACI treatment. a Cells were treated with
suberoylanilide hydroxamic acid (SAHA) (4 μM) for 48 h. Control cells
received the same volume of DMSO. Cytosolic extracts were
immunoprecipitated using an anti-acetyl-lysine antibody. (K-103).
Normal mouse serum (NMS) using HEK-293T cytosolic extracts was
used as a negative control. The immunoprecipitated complex was
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), and the blot was probed with an anti-Ku70 antibody. b, c
ES2 cells were treated with TSA (10 μM) for 48 h. HEK-293Tcells were
treated with SAHA (4 μM) for 48 h. Cytosolic extracts were
immunoprecipitated using anti-Bax antibodies. Normal rabbit serum
(NRS) was used as a control. The immunocomplexes were separated by
SDS-PAGE, and the blot was probed with Bax or Ku70 antibodies
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constantly receive stimuli, including death signals that
affect cell viability. Some of the death stimuli may lead
to apoptosis, while some of these small stimuli may only
activate a few Bax molecules. As a survival mechanism,
cells do not want to commit to die after receiving weak
signals that activate only small amount of Bax. To sur-
vive these aberrant Bax activation signals, cells design a
mechanism to block these signals. We believe that Ku70
may act as a survival factor, blocking the small amount
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This model suggests that because there is only a small
amount of Ku70 that binds to a small amount of Bax, addi-
tional Ku70 may be needed when more Bax is activated.
However, where does the additional Ku70 come from if
there is no free Ku70, and all remaining Ku70 that does
not bind Bax is in complex with other factors? This model
suggests another level of regulation of Ku70-Bax binding,
in which Ku70 has to be released from other complexes to
be available to bind to activated Bax. Studies have shown
that Ku70 binds to several factors in the cytosol [20–22].
For example, the FADD-like interleukin-1β-converting
enzyme (FLICE)-inhibitory protein (FLIP) is an anti-
apoptotic protein blocking caspase 8 activation by death
receptors [23]. However, FLIP, like Bax, also binds to
Ku70 in an acetylation-dependent manner. FLIP binds to
the Ku80-binding domain of Ku70. When Ku70 is acety-
lated at the same two lysines, K539 and K542, that regulate
Bax binding, this will also dissociate FLIP, triggering FLIP
polyubiquitination and degradation. This model suggests
that Ku70 regulates apoptosis via the intrinsic pathway
through Bax and the extrinsic pathway through caspase 8
[23]. Whether FLIP and Bax bind to Ku70 simultaneously
and dissociate from Ku70 when Ku70 is acetylated at K539
and K542 is not clear.
Ku80 is a DNA-binding partner of Ku70 in the nucle-
us. Our results also show that Ku80 binds to Ku70 in the
cytosol forming a higher molecular weight complex
(Fig. 1b). This complex formation is not affected by
HDACI treatment (Fig. 2a). However, unlike cytosolic
Ku70, Ku80 does not bind Bax (Fig. 2a). These results
are also consistent with the report by Sawada et al.
showing that Ku80 does not bind Bax and that Ku70
does not bind Bax and Ku80, simultaneously [5].
Whether the Ku70-Ku80 complex can regulate Ku70-
Bax binding remains to be determined.
Another issue we addressed in this study is whether Ku70
that acts as a survival factor, which we established using SH-
SY5Y cells, is also applicable to other cell types. Our results
show that we can clearly distinguish between two cell types
based on their response to Ku70 depletion: Ku70-depletion
sensitive cells, in which Ku70 depletion kills cells (such as
in N-type NB cells) (Fig. 3b), and Ku70-depletion less sensi-
tive cells (such as SHEP-1, ES2, A2780, and HEK-293Tcells)
(Fig. 3a), in which Ku70-depletion does not kill cells.
To investigate the mechanism by which these two cell
types differ in their regulation of cell death by Ku70, we treat-
ed these two cell types with HDACI. We have previously
shown that, in SH-SY5Y cells, HDACI treatment induced
cytosolic Ku70 acetylation and resulted in Bax release from
Ku70. The released Bax translocates into mitochondria, caus-
ing cytochrome c release, triggering cell death [17, 18]. In this
study, our results show that Ku70-depletion less sensitive cells
are less sensitive to HDACI-induced killing (Fig. 4c). Most
importantly, cytosolic Ku70 is acetylated in these cells follow-
ing HDACI treatment (Fig. 5a), but Bax is not released from
Ku70. These results suggest that Ku70 acetylation regulation
of Bax release in Ku70-depletion sensitive cells must be dif-
ferent in that in the Ku70-depletion less sensitive cells. To
confirm whether Bax is activated in Ku70-depletion less sen-
sitive cells even after HDACI-induced Ku70 acetylation, we
immunoprecipitated Bax using a Bax antibody (6A7) that
specifically recognizes the N-terminal of Bax when it is ex-
posed when activated [19]. Our results show that apoptosis
and Bax activation did not occur following HDACI treatment
in the Ku70-depletion less sensitive cells, while apoptotic ini-
tiation (increased in phosphatidylserine) and Bax activation
were found in Ku70-depletion sensitive cells following
HDACI treatment (Fig. 6a, b). Furthermore, HDACI treat-
ment induced Bax translocation to the mitochondria in
Ku70-depletion sensitive cells but not in Ku70-depletion in-
sensitive cells (Fig. 6c). Also, cleavage of pro-caspase 3, a
downstream target of Bax activation, is increased in Ku70-
depletion sensitive cells following HDACI treatment but not
in Ku70-depletion less sensitive cells (Fig. 6d). These results
suggest that the Ku70 regulation of Bax in the Ku70-depletion
less sensitive cells must be different from the conventional
model, in which Bax binding to the Bax-binding domain of
Ku70 is regulated by the acetylation at K539 and K542 [10].
The two lysines are localized at the linker region of Ku70, not
within the Bax-binding domain localized at the carboxyl ter-
minal of Ku70. Acetylation of these two lysines induces a
conformational change of the Bax-binding domain of Ku70,
which resulted in Bax dissociation. Our model suggests that
some other factors must be affecting the conformational
change of Ku70 upon acetylation of these two lysines. These
factors must be small because in gel filtration analyses, the
pattern of Ku70 and Bax chromatograph is similar in HEK-
293T cells compared to that of the SH-SY5Y cells (Figs. 1a
and 4b). Another possibility is that the Ku70-depletion less
sensitive cells have higher level of anti-apoptotic Bcl-2 family
Fig. 6 Bax is activated in SH-SY5Y cells but not in HEK-293T cells
following HDACI treatment. a, b, d SH-SY5Yor HEK-293T cells were
treated with suberoylanilide hydroxamic acid (SAHA) (4 μM) for 24 h.
Control cells received only DMSO. a The cells were washed, suspended
in annexin-binding buffer, and stained with annexin V-APC and PI.
Induction of apoptosis was measured using a CyAn ADP Analyzer
(Beckman Coulter, Inc., Indianapolis, IN) at the University of Michigan
flow cytometry core. bCytosolic extracts were immunoprecipitated using
an anti-Bax antibody or an anti-activated Bax antibody (6A7). Normal
rabbit serum (NRS) or normal mouse serum (NMS)was used as a control.
Immunocomplexes were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), and the blot was
probed with anti-Bax antibodies. c SH-SY5Y or HEK-293T cells were
treated with SAHA (4 μM) for 0, 2, 4, or 8 h as shown. Themitochondrial
extracts were analyzed by SDS-PAGE, and the blot was probed with anti-
Bax or anti-COX IV antibodies. d Cytosolic extracts were analyzed by
SDS-PAGE, and the blot was probed with anti-caspase 3 antibodies. β-
Tubulin was used as a loading control
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of proteins suppressing the activation of Bax and its associa-
tion from Ku70 when Ku70 is acetylated.
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